NCT06502145View on ClinicalTrials.gov

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine Level -1

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Azacitidine Level 0

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Azacitidine Level 1

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Iadademstat Level -1

75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.

DRUG

Iadademstat Level 0

75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

DRUG

Iadademstat Level 1

100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

Trial Locations (1)

53226

RECRUITING

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER